算法驱动的混合闭环在幼儿1型糖尿病中的启动和适应:一项试点研究。

IF 5.7 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Jacopo Pavan, Erin Cobry, Zachariah W Reed, María F Villa-Tamayo, Jenny L Diaz C, Mark D DeBoer, Melissa Schoelwer, Emily Jost, Ryan Kingman, Viola Holmes, John W Lum, Chaitanya L K Koravi, Bruce Buckingham, Roy Beck, R Paul Wadwa, Marc D Breton
{"title":"算法驱动的混合闭环在幼儿1型糖尿病中的启动和适应:一项试点研究。","authors":"Jacopo Pavan, Erin Cobry, Zachariah W Reed, María F Villa-Tamayo, Jenny L Diaz C, Mark D DeBoer, Melissa Schoelwer, Emily Jost, Ryan Kingman, Viola Holmes, John W Lum, Chaitanya L K Koravi, Bruce Buckingham, Roy Beck, R Paul Wadwa, Marc D Breton","doi":"10.1089/dia.2024.0650","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Introduction:</i></b> Glucose regulation in young children is complicated by higher glycemic variability, unpredictable behaviors, and low insulin needs. While the benefits of automated insulin delivery (AID) for this population are established, how to initiate and adjust pump settings still represents a challenging task for health care providers. In this study, we investigate the safety and efficacy of using algorithm-driven initiation and adjustments of AID parameters in children aged 2-6 years. <b><i>Methods:</i></b> Participants used AID at home for 8 weeks. Initial settings and periodic adjustments of therapy profiles (basal rates, insulin-to-carbohydrate ratios, insulin-correction factors, and sleep schedules) were provided through a cloud-based investigational software. Investigators reviewed therapy recommendations and could adjust if necessary. Primary safety endpoints included the percentage of time <54 mg/dL and >250 mg/dL, tested for noninferiority with respect to baseline. Primary efficacy endpoints (tested in a hierarchical manner) were the percentage of time in 70-180 mg/dL, mean glucose, the percentage of time >250 mg/dL, <70 mg/dL, and <54 mg/dL. <b><i>Results:</i></b> Thirty-two participants (age range: 2.0-5.9 years) were recruited for the study; 29 had sufficient data for the analysis. Investigators overrode 15% of software recommendations. The percentage of time <54 mg/dL and >250 mg/dL was noninferior in the 8-week follow-up with respect to baseline (<i>P</i> < 0.001). Statistically significant improvements were observed in the percentage of time in 70-180 mg/dL (<i>P</i> = 0.005), >250 mg/dL (<i>P</i> = 0.003), and mean glucose (<i>P</i> = 0.02). No difference was observed in the percentage of time <70 mg/dL (<i>P</i> = 0.34). Furthermore, no difference was observed with respect to a similar study cohort (same age range, <i>n</i> = 86) with expert pediatric endocrinologists modifying pump settings. <b><i>Conclusions:</i></b> Findings from this pilot study suggest that the use of AID with algorithm-driven initiation and adjustment of pump parameters is safe and effective in young children with type 1 diabetes. Further study of the algorithm in a larger cohort is indicated. Clinical Trials Registration number: NCT06017089.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Algorithm-Driven Initiation and Adaptation of Hybrid Closed-Loop in Young Children with Type 1 Diabetes: A Pilot Study.\",\"authors\":\"Jacopo Pavan, Erin Cobry, Zachariah W Reed, María F Villa-Tamayo, Jenny L Diaz C, Mark D DeBoer, Melissa Schoelwer, Emily Jost, Ryan Kingman, Viola Holmes, John W Lum, Chaitanya L K Koravi, Bruce Buckingham, Roy Beck, R Paul Wadwa, Marc D Breton\",\"doi\":\"10.1089/dia.2024.0650\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Introduction:</i></b> Glucose regulation in young children is complicated by higher glycemic variability, unpredictable behaviors, and low insulin needs. While the benefits of automated insulin delivery (AID) for this population are established, how to initiate and adjust pump settings still represents a challenging task for health care providers. In this study, we investigate the safety and efficacy of using algorithm-driven initiation and adjustments of AID parameters in children aged 2-6 years. <b><i>Methods:</i></b> Participants used AID at home for 8 weeks. Initial settings and periodic adjustments of therapy profiles (basal rates, insulin-to-carbohydrate ratios, insulin-correction factors, and sleep schedules) were provided through a cloud-based investigational software. Investigators reviewed therapy recommendations and could adjust if necessary. Primary safety endpoints included the percentage of time <54 mg/dL and >250 mg/dL, tested for noninferiority with respect to baseline. Primary efficacy endpoints (tested in a hierarchical manner) were the percentage of time in 70-180 mg/dL, mean glucose, the percentage of time >250 mg/dL, <70 mg/dL, and <54 mg/dL. <b><i>Results:</i></b> Thirty-two participants (age range: 2.0-5.9 years) were recruited for the study; 29 had sufficient data for the analysis. Investigators overrode 15% of software recommendations. The percentage of time <54 mg/dL and >250 mg/dL was noninferior in the 8-week follow-up with respect to baseline (<i>P</i> < 0.001). Statistically significant improvements were observed in the percentage of time in 70-180 mg/dL (<i>P</i> = 0.005), >250 mg/dL (<i>P</i> = 0.003), and mean glucose (<i>P</i> = 0.02). No difference was observed in the percentage of time <70 mg/dL (<i>P</i> = 0.34). Furthermore, no difference was observed with respect to a similar study cohort (same age range, <i>n</i> = 86) with expert pediatric endocrinologists modifying pump settings. <b><i>Conclusions:</i></b> Findings from this pilot study suggest that the use of AID with algorithm-driven initiation and adjustment of pump parameters is safe and effective in young children with type 1 diabetes. Further study of the algorithm in a larger cohort is indicated. Clinical Trials Registration number: NCT06017089.</p>\",\"PeriodicalId\":11159,\"journal\":{\"name\":\"Diabetes technology & therapeutics\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2025-03-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes technology & therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/dia.2024.0650\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes technology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/dia.2024.0650","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

幼儿的血糖调节因较高的血糖变异性、不可预测的行为和较低的胰岛素需求而变得复杂。虽然自动化胰岛素输送(AID)对这一人群的益处已经确立,但如何启动和调整泵设置仍然是卫生保健提供者面临的一项具有挑战性的任务。在本研究中,我们研究了在2-6岁儿童中使用算法驱动启动和调整AID参数的安全性和有效性。方法:参与者在家中使用AID治疗8周。初始设置和治疗方案的周期性调整(基础比率、胰岛素-碳水化合物比率、胰岛素校正因子和睡眠时间表)通过基于云的研究软件提供。研究人员回顾了治疗建议,并在必要时进行调整。主要安全终点包括250 mg/dL的时间百分比,相对于基线进行了非劣效性测试。主要疗效终点(以分层方式测试)是70- 180mg /dL的时间百分比,平均葡萄糖,> 250mg /dL的时间百分比。结果:32名参与者(年龄范围:2.0-5.9岁)被招募参加研究;29个国家有足够的数据进行分析。调查人员推翻了15%的软件建议。在8周的随访中,250 mg/dL的时间百分比与基线无关(P < 0.001)。在70-180 mg/dL (P = 0.005)、50 - 250 mg/dL (P = 0.003)和平均血糖(P = 0.02)中观察到有统计学意义的改善。时间百分比差异无统计学意义(P = 0.34)。此外,在一个相似的研究队列(相同年龄范围,n = 86)中,儿科内分泌专家修改了泵的设置,没有观察到差异。结论:这项初步研究的结果表明,在幼儿1型糖尿病患者中,使用由算法驱动的启动和调整泵参数的AID是安全有效的。在更大的队列中进一步研究该算法。临床试验注册号:NCT06017089。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Algorithm-Driven Initiation and Adaptation of Hybrid Closed-Loop in Young Children with Type 1 Diabetes: A Pilot Study.

Introduction: Glucose regulation in young children is complicated by higher glycemic variability, unpredictable behaviors, and low insulin needs. While the benefits of automated insulin delivery (AID) for this population are established, how to initiate and adjust pump settings still represents a challenging task for health care providers. In this study, we investigate the safety and efficacy of using algorithm-driven initiation and adjustments of AID parameters in children aged 2-6 years. Methods: Participants used AID at home for 8 weeks. Initial settings and periodic adjustments of therapy profiles (basal rates, insulin-to-carbohydrate ratios, insulin-correction factors, and sleep schedules) were provided through a cloud-based investigational software. Investigators reviewed therapy recommendations and could adjust if necessary. Primary safety endpoints included the percentage of time <54 mg/dL and >250 mg/dL, tested for noninferiority with respect to baseline. Primary efficacy endpoints (tested in a hierarchical manner) were the percentage of time in 70-180 mg/dL, mean glucose, the percentage of time >250 mg/dL, <70 mg/dL, and <54 mg/dL. Results: Thirty-two participants (age range: 2.0-5.9 years) were recruited for the study; 29 had sufficient data for the analysis. Investigators overrode 15% of software recommendations. The percentage of time <54 mg/dL and >250 mg/dL was noninferior in the 8-week follow-up with respect to baseline (P < 0.001). Statistically significant improvements were observed in the percentage of time in 70-180 mg/dL (P = 0.005), >250 mg/dL (P = 0.003), and mean glucose (P = 0.02). No difference was observed in the percentage of time <70 mg/dL (P = 0.34). Furthermore, no difference was observed with respect to a similar study cohort (same age range, n = 86) with expert pediatric endocrinologists modifying pump settings. Conclusions: Findings from this pilot study suggest that the use of AID with algorithm-driven initiation and adjustment of pump parameters is safe and effective in young children with type 1 diabetes. Further study of the algorithm in a larger cohort is indicated. Clinical Trials Registration number: NCT06017089.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Diabetes technology & therapeutics
Diabetes technology & therapeutics 医学-内分泌学与代谢
CiteScore
10.60
自引率
14.80%
发文量
145
审稿时长
3-8 weeks
期刊介绍: Diabetes Technology & Therapeutics is the only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes. This leading international journal delivers practical information and comprehensive coverage of cutting-edge technologies and therapeutics in the field, and each issue highlights new pharmacological and device developments to optimize patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信